Man with diabetes reaching his A1C goal with Xultophy® 100/3.6 Man with diabetes reaching his A1C goal with Xultophy® 100/3.6 Man with diabetes reaching his A1C goal with Xultophy® 100/3.6

Xultophy® 100/3.6  & A1C

Reaching an A1C of less than 7% is a goal shared by many people with type 2 diabetes. See how Xultophy® 100/3.6 performed in clinical studies.

Xultophy® 100/3.6 is clinically proven to significantly lower A1C


People taking Xultophy® 100/3.6 experienced an average weight reduction of 3 pounds, while those taking Lantus® gained an average of 4 pounds.d
 

aAverage end-of-trial dose was 41 units of Xultophy® 100/3.6 and 66 units of Lantus®. The clinical importance of this difference is uncertain. Doses could not be increased by more than 4 units per week and there was no maximum dose of Lantus®. A1C results may not reflect those seen outside a clinical study, where different doses of Lantus® can be used.
bStudy C compared Xultophy® 100/3.6 with the long-acting insulin, Lantus®. Those taking Lantus® lowered their A1C an average 1.16% points (from 8.2 to 7.1), while those switching to Xultophy® 100/3.6 dropped 1.67% points.
cIndividual results may vary from results in clinical studies.
dWeight gain can occur with insulin-containing products like Xultophy® 100/3.6.
 

Add another medicine without adding another injection

A single daily dose of Xultophy® 100/3.6 works for a full 24 hours and showed similar A1C results to 1 long-acting and up to 4 mealtime insulin injections. One dose of Xultophy® 100/3.6 can be taken at the same time each day, with or without food and controls blood sugar in 2 ways:

  • By adding insulin when your body isn’t making enough to lower blood sugar throughout the day
  • By helping your pancreas work better to produce more insulin when your blood sugar levels are high

People taking Xultophy® 100/3.6 experienced an average weight reduction of 2 pounds, while those taking Lantus® and NovoLog® gained an average of 6 pounds.d

cIndividual results may vary from results in clinical studies.
dWeight gain can occur with insulin-containing products like Xultophy® 100/3.6.
eDUAL™ VII trial compared Xultophy® 100/3.6 with NovoLog® plus the long-acting insulin, Lantus®. Those taking NovoLog® and Lantus® lowered their A1C an average 1.5% (from 8.2 to 6.7), while those switching to Xultophy® 100/3.6 demonstrated similar A1C reduction.
fAverage end-of-trial dose was 40 units of Xultophy® 100/3.6 vs 52 units basal + 32 units bolus. People could not increase their basal insulin or Xultophy® 100/3.6 dose by more than 4 units per week. A1C results may not reflect those seen outside a clinical study, where different doses of Lantus® and NovoLog® can be used.
 

Across clinical studies, Xultophy® 100/3.6 helped the majority of people reach an average A1C of less than 7%, the American Diabetes Association (ADA) goal.c,f

Across all clinical studies, Xultophy® 100/3.6 helped lower A1C

The percentage of people who reached the ADA A1C goal across 3 clinical studies for Xultophy® 100/3.6 ranged from 57.3% to 68.3%.

aAverage end-of-trial dose was 41 units of Xultophy® 100/3.6 and 66 units of Lantus®. The clinical importance of this difference is uncertain. Doses could not be increased by more than 4 units per week and there was no maximum dose of Lantus®. A1C results may not reflect those seen outside a clinical study, where different doses of Lantus® can be used. 
bStudy C compared Xultophy® 100/3.6 with the long-acting insulin, Lantus®. Those taking Lantus® lowered their A1C an average 1.16% points (from 8.2 to 7.1), while those switching to Xultophy® 100/3.6 dropped 1.67% points.
cIndividual results may vary from results in clinical studies.
dDUAL™ VII trial compared Xultophy® 100/3.6 with NovoLog® plus the long-acting insulin, Lantus®. Those taking NovoLog® and Lantus® lowered their A1C an average 1.5% (from 8.2 to 6.7), while those switching to Xultophy® 100/3.6 demonstrated similar A1C reduction.
eAverage end-of-trial dose was 40 units of Xultophy® 100/3.6 vs 52 units basal + 32 units bolus. People could not increase their basal insulin or Xultophy® 100/3.6 dose by more than 4 units per week. A1C results may not reflect those seen outside a clinical study, where different doses of Lantus® and NovoLog® can be used.
fThree 26-week, head-to-head studies were done involving more than 1400 people with type 2 diabetes.
gStudy B compared Xultophy® 100/3.6 with a long-acting insulin. Those taking long-acting insulin lowered their A1C an average 1.05% points (from 8.8 to 7.7), while those switching to Xultophy® 100/3.6 dropped 1.94% points. End-of-study doses of both medicines was 46 units.

Xultophy® 100/3.6 Savings Card

Save on Xultophy® 100/3.6

With the Xultophy® 100/3.6 Savings Card, eligible patients pay as little as $1 per day. With your card, you’ll receive a free box of Novo Nordisk needles and a maximum monthly savings of $400 for up to 24 months. Eligibility and other restrictions apply.

Request a Savings Card

Woman preparing to talk with her doctor about Xultophy® 100/3.6 Woman preparing to talk with her doctor about Xultophy® 100/3.6 Woman preparing to talk with her doctor about Xultophy® 100/3.6
Woman preparing to talk with her doctor about Xultophy® 100/3.6

We've compiled some questions to help guide the conversation with your health care provider at your next appointment.

Get questions for your doctor